Study of the Cognition of Patients Treated With Immunotherapy

Study Overview
=================
Brief Summary
-----------------
The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology. Due to the recent nature of immunotherapy, its side effects and impact on quality of life are still poorly understood and, to date, there is no published study evaluating the impact of immunotherapy on cognition in patients treated for cancer. The study consists of the passation of 3 neuropsychological assessments over a period of 6 months in cancer patients who start immunotherapy

Official Title
-----------------
Study of the Cognition of Patients Treated With

Conditions
-----------------
Patients With Cancer Who Start Immunotherapy, All Neoplasms

Intervention / Treatment
-----------------
* Other: Cognitive test passations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over the age of 18, Patient with cancer and having to initiate treatment with immunotherapy alone Treatment with immunotherapy will include either an anti-PD1 / L1 or Anti CTLA4 monotherapy or combination, Patients may have received other antitumor treatments other than immunotherapy but these should be stopped at the time of initiation of immunotherapy Performance Status <2 Patient at the level of studies 3 end of primary studies minimum (Barbizet scale), Mastery of the French language. Patient affiliated to a social security system Patient having attested in writing of his non-opposition to participate in the study Exclusion Criteria: Previous treatment with immunotherapy Another anti-tumor treatment underway Primary cancer of the central nervous system or cerebral metastasis, symptomatics and not controlled Abuse of alcohol or drug use Severe visual and / or auditory deficiency, Refusal of participation of the patient. Patient deprived of liberty or under guardianship Patient unable to follow the study for geographical, social or psychopathological reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Cognitive test passations<br>3 neuropsychological passations over a period of 6 months. | Other: Cognitive test passations<br>* Tests : MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognitive function (at least in a cognitive domain) | The proportion of patients who will have a reduction of scores in neuropsychological questionnaires (scores of MoCA2, Hopkins verbal learning test, WAIS-IV, Trail Making test, Stroop Symboles) | between inclusion and 3 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunotherapy, Cognition, Cancer